Varda raises $250 million at $1.6 billion valuation to scale orbital drug manufacturing

•26d ago

Varda raises $250 million at $1.6 billion valuation to scale orbital drug manufacturing

Tap title to read story

In-space manufacturing startup Varda Space has closed a two-hundred-fifty-million-dollar Series D funding round at a one-point-six-billion-dollar valuation, as announced by the company. Led by Lux Capital and Natural Capital, the latest financing brings Varda's total capital raised to five-hundred-ninety-eight million dollars since its founding in 2021. Based in El Segundo, California, Varda develops uncrewed space capsules designed to function as microgravity orbital laboratories for pharmaceutical development and commercial material processing. The company has deployed six missions to orbit using its W-Series capsules, with five successfully returning to Earth. Varda plans to launch two capsules simultaneously on an upcoming SpaceX Falcon 9 rideshare mission, carrying hypersonic research payloads for the Pentagon and commercial clients. While about seventy percent of current payload customers are government-related, the firm aims to transition toward commercial pharmaceutical production, targeting human clinical trials of space-manufactured formulations near the end of the decade.

0:00 / 0:56

In-space manufacturing startup Varda Space has closed a two-hundred-fifty-million-dollar Series D funding round at a one-point-six-billion-dollar valuation, as announced by the company. Led by Lux Capital and Natural Capital, the latest financing brings Varda's total capital raised to five-hundred-ninety-eight million dollars since its founding in 2021. Based in El Segundo, California, Varda develops uncrewed space capsules designed to function as microgravity orbital laboratories for pharmaceutical development and commercial material processing. The company has deployed six missions to orbit using its W-Series capsules, with five successfully returning to Earth. Varda plans to launch two capsules simultaneously on an upcoming SpaceX Falcon 9 rideshare mission, carrying hypersonic research payloads for the Pentagon and commercial clients. While about seventy percent of current payload customers are government-related, the firm aims to transition toward commercial pharmaceutical production, targeting human clinical trials of space-manufactured formulations near the end of the decade.

Published 2026-09-30 10:43:12 UTC · Published by JQJO

Published by JQJO Editorial Desk · AI assisted

More context

Timeline

2021 — On 2021 Varda Space was founded by chief executive officer Will Bruey.
2023 — On 2023 Varda deployed its first mission to orbit with W-Series capsule.
2026-08 — On August 2026 biotechnology executive Mikael Dolsten was appointed to board.
2026-09 — On September 2026 company closed two-hundred-fifty-million-dollar Series D funding round.
2026-09 — On September 2026 valuation reached one-point-six-billion-dollar milestone following new investment.
2026-09 — On Thursday 2026 Varda plans to launch two capsules simultaneously to space.
2027 — On 2027 Varda has scheduled twenty-eight commercial launch bookings through 2029.
2030 — On 2030 company plans to debut next-generation orbital manufacturing capsule.
2030 — On 2030 International Space Station faces scheduled retirement affecting research platforms.
2032 — On 2032 company expects commercial pharmaceutical payload proportion to flip.

Why it matters

Immediate US impact: Immediate US impact involves expanded defense hypersonic research payload capabilities. Possible long-term US impact: Long-term US impact establishes commercial pharmaceutical manufacturing in microgravity environments. Most affected groups: Most affected groups include aerospace companies, pharmaceutical researchers, and defense contractors. Reader priority: Readers should prioritize primary company announcements and verified aerospace industry reporting.

Coverage notes

Left: Emphasizes regulatory oversight and government defense contract reliance. Center: Reports funding valuation milestones and pharmaceutical manufacturing objectives neutrally. Right: Highlights private market capitalization growth and commercial space innovation.